David Hallifax

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4238511/publications.pdf

Version: 2024-02-01

26 papers	3,324 citations	346980 22 h-index	591227 27 g-index

27 all docs	27 docs citations	27 times ranked	3626 citing authors

#	Article	IF	Citations
1	Utilising Magnetically Isolated Lysosomes for Direct Quantification of Intralysosomal Drug Concentrations by LC-MS/MS Analysis: An Investigatory Study With Imipramine. Journal of Pharmaceutical Sciences, 2020, 109, 2891-2901.	1.6	2
2	Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance. Drug Metabolism and Disposition, 2018, 46, 268-278.	1.7	25
3	Clearance Prediction Methodology Needs Fundamental Improvement: Trends Common to Rat and Human Hepatocytes/Microsomes and Implications for Experimental Methodology. Drug Metabolism and Disposition, 2017, 45, 1178-1188.	1.7	113
4	Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins. Xenobiotica, 2015, 45, 847-857.	0.5	6
5	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology, 2013, 87, 1315-1530.	1.9	1,089
6	Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs. Drug Metabolism and Disposition, 2012, 40, 104-110.	1.7	61
7	Evaluation of Hepatic Clearance Prediction Using In Vitro Data: Emphasis on Fraction Unbound in Plasma and Drug Ionisation Using a Database of 107 Drugs. Journal of Pharmaceutical Sciences, 2012, 101, 2645-2652.	1.6	51
8	Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: Comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs. European Journal of Pharmaceutical Sciences, 2012, 45, 570-574.	1.9	21
9	Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction ofin vivoclearance. Xenobiotica, 2011, 41, 124-136.	0.5	37
10	Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View. Pharmaceutical Research, 2010, 27, 2150-2161.	1.7	159
11	Metabolite Formation Kinetics and Intrinsic Clearance of Phenacetin, Tolbutamide, Alprazolam, and Midazolam in Adenoviral Cytochrome P450-Transfected HepG2 Cells and Comparison with Hepatocytes and In Vivo. Drug Metabolism and Disposition, 2010, 38, 1449-1455.	1.7	27
12	Methodological Uncertainty in Quantitative Prediction of Human Hepatic Clearance from In Vitro Experimental Systems. Current Drug Metabolism, 2009, 10, 307-321.	0.7	51
13	Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica, 2008, 38, 353-367.	0.5	30
14	Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction. Drug Metabolism and Disposition, 2007, 35, 1325-1332.	1.7	65
15	Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies. Drug Metabolism Reviews, 2007, 39, 159-234.	1.5	673
16	BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT: Fig. 1.. Drug Metabolism and Disposition, 2006, 34, 724-726.	1.7	153
17	Prediction of In Vivo Drug-Drug Interactions from In Vitro Data. Clinical Pharmacokinetics, 2006, 45, 1035-1050.	1.6	121
18	Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance. Drug Metabolism and Disposition, 2006, 34, 1829-1836.	1.7	53

#	Article	IF	Citations
19	PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES. Drug Metabolism and Disposition, 2005, 33, 1852-8.	1.7	42
20	CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 180-190.	1.3	157
21	IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM. Drug Metabolism and Disposition, 2005, 33, 837-844.	1.7	150
22	Microsomal prediction ofin vivoclearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica, 2005, 35, 603-625.	0.5	45
23	Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metabolism and Disposition, 2005, 33, 837-44.	1.7	35
24	UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES. Drug Metabolism and Disposition, 2004, 32, 1411-1420.	1.7	73
25	QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES. Drug Metabolism and Disposition, 2004, 32, 572-580.	1.7	21
26	Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo. Pharmaceutical Research, 2004, 21, 819-826.	1.7	62